

November 13, 2018

The Secretary, BSE Ltd, Rotunda Building, 1<sup>st</sup> Floor, Phiroze Jeejeebhai Towers, New Trading Wing, Dalal Street, Mumbai – 400 001.

Dear Sir,

Sub: Unaudited Results for Quarter and Six Months ended 30<sup>th</sup> September 2018 – Reg Ref: 1) Regulation 33 of the Securities and Exchange Board of Inda (Listing Obligations and Disclosure Requirement) Regulations, 2015 2) Scrip Code: 526783 3) Our Letter dated November 5, 2018

We would like to inform you that Board Meeting held today, the Board of Directors approved the Unaudited Financial Results for the Second Quarter and half year ended September 30, 2018. A Copy of the un-audited Financial Results along with the Limited Review report of the Independent Auditors is enclosed for your information and records.

The above information is also available on our website at www.dragarwal.com

Kindly take the above information on record.

Thanking you,

Yours faithfully,

DR. AMÁR AGARWAL CHAIRMAN CUM MANAGING DIRECTOR DR. AGARWAL'S EYE HOSPITAL LTD

## **Registered Office**

3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai-600 006. Tel: +91-44-3991 6600 / 3991 6669 Fax: 91-44-3991 6645 Corporate ID Number: L85110TN1994PLC027366 Email: dragarwal@vsnl.com | Website: www.dragarwal.com

## Deloitte Haskins & Sells

Chartered Accountants ASV N Ramana Tower 52, Venkatnarayana Road T. Nagar Chennai - 600 017 Tamil Nadu, India

Tel: +91 44 6688 5000 Fax: +91 44 6688 5050

## INDEPENDENT AUDITOR'S REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

## TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter and half year ended 30 September 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

Jaideep S Trasi Partner (Membership No. 211095)

CHENNAI, 13 November 2018 JT/RB/2018/117



	Dr. Agarwaf's Eye Hospital Limited Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CiN : L85110TN1994PLC027366 Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2018	I Results for the Quarter					
			Out the Forded		(Amount Rs. In Lakh Half Year Ended	Amount Rs. In Lakhs except earnings per share data Half Vear Ended	ngs per share data Vear Ended
S.No.	Particulars	30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31-Mar-18
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income	4.395.01	4.439.10	3,930.07	8,834,11	8,113.39	15.332.13
	(a) Revenue Irom Operations	32.50	43.46	47.33	75.96	68.19	230.00
	Total Income	4,427.51	4,482.56	3,977.40	8,910.07	8,181.58	15,562.13
2	Expenses		and the second sec		07 014	. 050.00	74 906 4
	(a) Purchase of Stock-in-Trade	239.32	517.10	340.30	120.42	1460 801	12,060.1
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	69.26	(123,533)	40'0A	1 1 1 7 7 85	751.99	1 541.74
	(c) Consumables	000.32 6/3 57	580 68	475.98	1.184.25	972.62	2,002.75
	I(d) Consultancy Unarges	901 60	852.35	809.19	1,744.04	1,571,55	3,198.03
	(e) Employee Dete	64.89	47.37	52.70	112.26	105.95	259.04
	(a) Depreciation and Amortisation Expense	239.48	229.27	255.41	468.75	469.41	978,18
	(h) Rent	465.77	421.79	413.94	887.56	837.06	1.717.98
	(i) Other Expenses	649.76	696.73	573.80	1.346.49	1,214.55	2,/13.6/
	Total Expenses	3,830.06	3,743.29	3,350.50	7,573,35	6,814.11	14,220.04
3	Profit before Exceptional Items and Tax (1-2)	597.45	739.27	626.90	1,336.72	1,366.81	1,335.05
4	Exceptional Items	4			-	* 900 P	00 300 10
5	Profit before Tax (3-4)	597.45	139.27	626.30	1,330.12	10.000.1	A'000'1
9	Tax Expense	US DAC	Dag an	UN DCC	436 60	524.30	644,35
	- Current Lax (incuduring prior years)	(1 05)	(10 53)	112 101	(20.58)	(51.21)	14.22
	- Detertion Tax	397.70	523.00	410.00	920.70	893.72	677.52
- 8	Other Comprehensive Income						
	I(a) Items that will not be reclassified to the Statement of Profit and Loss					Constant of the second	
	- Actuarial loss on defined benefit obligation	(8.81)	(9.55)	(8.26)	(18.36)	(16.61)	(38.19)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	2.57	2.78	2.86	5.35	5.75	11.12
	(b) Items that will be reclassified to the Statement of Profit and Loss						
	Total Other Comprehensive Loss (net of tax)	(6.24)	(6.77)	(2:40)	(13.01)	(10.86)	(21.07)
6	Total Comprehensive Income (7+8)	391.46	516.23	404.60	907.69	882.85	C7-000
10	Paid-up equity share capital ( Face value Rs. 10/- each)	470.00	470.00	4/0.00	4/0.00	n0'0/#	3.035.91
11	Reserves (Other Equity)						
21	(a) Racio	8,46	11.13	8.72	19.59	19.02	14.42
	(b) Diluted	8.46	11.13	8.72	19.59	19.02	14.42
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)





05         30-569-18         Amount Rs. In Lakes         Amount St. In Lakes         343.82         34
155.56
1,212.62 155.56
9
25
6
-
-

CHENNAL-17

Dr. Agarwal's Eye Hospital Limited Dr. Agarwal's Eye Hospital Limited Regd Office: 3rd Fl.sor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennal - 600 006 Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366 Statement of Unaudited Financial Results for the Quarter and Hal' Year Ended 30 September 2018	The above unaudited financial results heve been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting hald on 13 November 2018. The above results for the quarter and half year ended 30 September 2015 has also been subject to limited review by the Statutory Auditors of the Company.	The Company operates in a single segment i.e. "Eye Care related Sales and Services" and hence, does not have any additional disclosures to be made under ind AS 108 - Operating Segments.	Device in April 2019, the Company has approved in the Company. The approval of the spareholders obtained on 100 AS 110 old not have any material impact on the financial results of the Company. Dividend of Rs. 56.40 Lakths has been paid during the quarter pursuant to the approval of the shareholders obtained on 30 August 2016.	By order of the Board Dr. Amar Agarwai	DIN No. 00435684	A A A A A A A A A A A A A A A A A A A
Regd Office Phone No. 91-44-39916665 Statement of	Notes: The above unaudited financial results have been raviewed by the ended 30 September 2015 has also been subject in limited review	<ol> <li>The Company operates in a single segment i.e. "Eye Care related 3 Fiftertise 1 and 2018 the Common New solvered IND. 45: 415 to.</li> </ol>	Dividend of Rs. 56.40 Lakhs has bee	e. Chennai	Date : 13 November 2018	PEC ACCOUNTING OF THE HASKING OF THE